Moore Capital Management’s Travere Therapeutics TVTX Stock Holding History

Moore Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,000	Closed	-$675K	–	594
2023 Q1	$675K	Buy	+30,000	New	+$638K	0.01%	308
2022 Q4	–	Sell	-191,724	Closed	-$4.72M	–	639
2022 Q3	$4.72M	Buy	191,724 +105,688	+123%	+$2.73M	0.11%	206
2022 Q2	$2.08M	Buy	86,036 +63,093	+275%	+$1.59M	0.06%	326
2022 Q1	$591K	Buy	+22,943	New	+$609K	0.02%	454
2015 Q3	–	Sell	-85,000	Closed	-$2.82M	–	405
2015 Q2	$2.82M	Buy	+85,000	New	+$2.33M	0.06%	272

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Moore Capital Management's TVTX Position: Q2 2023 in Review

Moore Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 30,000 shares — an estimated $675K sold.

Moore Capital Management first reported a position in TVTX in Q2 2015 and held it in 5 quarters. The position peaked at $4.72M in Q3 2022. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

Moore Capital Management reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
Moore Capital Management sold 30,000 Travere Therapeutics shares in Q2 2023, an estimated $675K.
Moore Capital Management first reported a position in Travere Therapeutics in Q2 2015 and held it in 5 quarters.
Moore Capital Management's Travere Therapeutics position peaked at $4.72M in Q3 2022.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Moore Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.